Cargando…

Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

BACKGROUND: Previous studies have shown that, overall, quality of life (QoL) decreases within the first 3–6 months after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC), returning to baseline levels by 6–12 months. This systematic review aims to evaluate the factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leimkühler, Maleen, Hentzen, Judith E. K. R., Hemmer, Patrick H. J., Been, Lukas B., van Ginkel, Robert J., Kruijff, Schelto, van Leeuwen, Barbara L., de Bock, Geertruida H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Peritoneal Surface Malignancy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471142/ https://www.ncbi.nlm.nih.gov/pubmed/32335752 http://dx.doi.org/10.1245/s10434-020-08379-9

Ejemplares similares

Surgeons’ Ability to Predict the Extent of Surgery Prior to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
por: Hentzen, Judith E. K. R., et al.
Publicado: (2020)

Coagulopathy and Venous Thromboembolic Events Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Dranichnikov, Paul, et al.
Publicado: (2021)

Predicting Early and Late Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Moon, Eui Whan, et al.
Publicado: (2021)

Functional Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Prospective Cohort Study
por: Makker, Preet G. S., et al.
Publicado: (2022)

Predischarge Prediction of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Derivation and Validation of a Risk Prediction Score
por: Rieser, Caroline J., et al.
Publicado: (2021)

Reply to: “Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does Not Deserve Its Bad Reputation”
por: Horvath, Philipp, et al.
Publicado: (2021)

Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Thorgersen, Ebbe Billmann, et al.
Publicado: (2021)

Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma
por: Dietz, Michelle V., et al.
Publicado: (2022)

Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit
por: Bhutiani, Neal, et al.
Publicado: (2023)

Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis
por: Lee, Suk Jun, et al.
Publicado: (2021)

RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases
por: Bhullar, Dilraj, et al.
Publicado: (2022)

Predictive Ability of C-Reactive Protein in Detecting Short-Term Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cross-Sectional Study
por: van Kooten, Job P., et al.
Publicado: (2020)

Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study
por: Kurreck, Annika, et al.
Publicado: (2021)

Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases
por: Ramanathan, Rajesh, et al.
Publicado: (2021)

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of ‘Italian Peritoneal Surface Malignancies Oncoteam—S.I.C.O.’
por: Marano, Luigi, et al.
Publicado: (2021)

In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany
por: Überrück, Lisa, et al.
Publicado: (2020)

A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma
por: Yurttas, Can, et al.
Publicado: (2021)

Use of Prognostic Factors and Scores in Selection of Patients with Colorectal Cancer Peritoneal Metastasis (CRPM) for Cytoreductive Surgery and Intraperitoneal Chemotherapy (CRS/IPC): Results of an International Survey Among Oncologic Clinicians
por: Kozman, Mathew A., et al.
Publicado: (2023)

Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial
por: Bakkers, C., et al.
Publicado: (2023)

Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?
por: Khan, Sohini, et al.
Publicado: (2022)

The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer
por: Jónsdóttir, Björg, et al.
Publicado: (2020)

Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
por: Di Donato, Violante, et al.
Publicado: (2020)

Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA
por: Raoof, Mustafa, et al.
Publicado: (2023)

Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases
por: El Asmar, Antoine, et al.
Publicado: (2022)

Prognostic Impact of Mesenteric Lymph Node Status on Digestive Resection Specimens During Cytoreductive Surgery for Ovarian Peritoneal Metastases
por: Channawi, Ali, et al.
Publicado: (2023)

Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases
por: Saito, Shin, et al.
Publicado: (2020)

The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis
por: Flood, Michael P., et al.
Publicado: (2022)

HIPEC-Induced Acute Kidney Injury: A Retrospective Clinical Study and Preclinical Model
por: Liesenfeld, Lukas F., et al.
Publicado: (2021)

Bidirectional Approach with PIPAC and Systemic Chemotherapy for Patients with Synchronous Gastric Cancer Peritoneal Metastases (GCPM)
por: Casella, Francesco, et al.
Publicado: (2023)

Treatment Strategies and Prognosis of Patients With Synchronous or Metachronous Colorectal Peritoneal Metastases: A Population-Based Study
por: Bakkers, C., et al.
Publicado: (2021)

Impact of sociodemographic factors on outcomes in patients with peritoneal malignancies following cytoreduction and chemoperfusion
por: Cantos, Adriana, et al.
Publicado: (2022)

Extensive Peritonectomy is an Independent Risk Factor for Cisplatin HIPEC-Induced Acute Kidney Injury
por: Liesenfeld, Lukas F., et al.
Publicado: (2022)

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
por: Meijer, T. Susanna, et al.
Publicado: (2020)

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer
por: Hübner, Martin, et al.
Publicado: (2023)

Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
por: Graf, Wilhelm, et al.
Publicado: (2019)

Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
por: Patrick-Brown, Thale Dawn J. H., et al.
Publicado: (2020)

In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
por: Said, Ibrahim, et al.
Publicado: (2022)

Gastric Cancer Peritoneal Carcinomatosis Risk Score
por: Ji, Liang, et al.
Publicado: (2019)

Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer
por: Senguttuvan, Rosemary N., et al.
Publicado: (2023)

Four-Point Computed Tomography Scores for Evaluation of Occult Peritoneal Metastasis in Patients with Gastric Cancer: A Region-to-Region Comparison with Staging Laparoscopy
por: Li, Zi-Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lkmfs2laron7pl3dma28ps2ffd